biosimilar portfolio

Mergers & Acquisitions Harman acquires Masimo’s audio arm in Samsung’s car audio push

Harman International Industries Inc., wholly owned by Samsung Electronics Co., has acquired Masimo Corp.’s audio business for $350 million, a ...

Bio & Pharma Korea’s pharmaceutical exports set to top $10 bn, led by ‘K-M7’ champions

South Korea’s pharmaceutical exports are on course to surpass $10 billion this year, underscoring the country’s growing clout in the glo...

Bio & Pharma Celltrion expands footprint in Latin America with flagship oncology drugs

South Korea’s biopharmaceutical giant Celltrion Inc. has solidified its presence in South America after winning supply contracts for its flags...

Bio & Pharma Celltrion wins Australian approval for eye, bone disease biosimilars

Celltrion Inc. said Wednesday it has received regulatory approval from Australia’s Therapeutic Goods Administration (TGA) for three biosimilar...

Bio & Pharma Celltrion to sell autoimmune drug Stelara biosimilar at Costco in US

South Korea’s leading biosimilar drug developer Celltrion Inc. said on Monday it is set to sell Steqeyma, a biosimilar to autoimmune disease t...

Cryptocurrencies BlackRock sees digital assets at critical turning point

Digital assets are poised for robust structural growth – not just as investment vehicles but as strategic assets – fueled by growing ins...

Pension funds S.Korea’s NPS to double pension fund size by 2050, hike risky assets

South Korea’s National Pension Service (NPS) is projected to nearly double its fund size to 3,500 trillion won ($2.38 trillion) by 2050, follo...

Batteries LG Energy, Doosan Bobcat tie up for construction equipment battery packs

LG Energy Solution Ltd., the world’s third-largest battery maker, and Doosan Bobcat Inc., a global construction machinery producer, said on We...

Pension funds S.Korea’s pension fund NPS to overhaul alternative investment strategy

The National Pension Service (NPS), South Korea’s state-run pension fund and the country’s largest institutional investor, plans to intr...

Bio & Pharma Samsung, Celltrion lead biosimilar market in Europe, US

Samsung Bioepis Co. and Celltrion Inc. are outpacing long-established global drug manufacturers such as Amgen Inc. and Sandoz in the antibody biosim...

Bio & Pharma Celltrion wins EU approval for autoimmune disease treatment Avtozma

Celltrion Inc.’s Avtozma, a biosimilar to Roche’s autoimmune disease treatment Actemra, has won approval from the European Commission, f...

Bio & Pharma Korean court rules in favor of Samsung Bioepis over Regeneron’s Eylea

A South Korean court on Friday ruled in favor of Samsung Bioepis Co. in a patent dispute against Regeneron Pharmaceuticals Inc., a US pharmaceutical...

Corporate restructuring SK Ecoplant seeks to sell waste treatment business for $1.4 billion

SK Ecoplant Co., a South Korean construction engineering and waste management company under SK Group, is seeking to dispose of its waste treatment b...

Corporate investment LX International seeks to acquire nickel, copper mines in Indonesia

LX International Corp., the trading unit of South Korea’s LX Group, said on Friday it is seeking to acquire a nickel mine and a copper mine in...

Bio & Pharma Celltrion’s Vegzelma: Most-prescribed cancer treatment in Europe

South Korea’s leading biosimilar drug developer Celltrion Inc.'s Vegzelma, a cancer drug referencing global biopharma Roche’s Avastin, h...

Bio & Pharma Korean drugmakers control more than half of European biosimilar market

South Korea’s two leading drugmakers, Celltrion Inc. and Samsung Bioepis Co., have achieved a significant milestone in the European biosimilar...

Bio & Pharma Celltrion obtains approval of Steqeyma from FDA

South Korea's Celltrion Inc. said on Wednesday it received new drug submission (NDS) approval from the Food and Drug Administration (FDA) for Steq...

Bio & Pharma Celltrion’s 4 new biosimilars win EU approval recommendation

Celltrion Inc. is one step closer to commercializing its four new biosimilars in Europe after a committee of the European Medicines Agency (EMA) rec...

Bio & Pharma Celltrion gets approval of Omlyclo in Canada

South Korea’s Celltrion Inc., received new drug submission (NDS) approval from Health Canada for Omlyclo, the biosimilar of allergic asthma an...

Executive reshuffles SK promotes restructuring keymen to SK On, SK Discovery top posts

SK Group on Thursday promoted the keymen of its business overhauls to top posts at intermediary holding company SK Discovery Co. and battery maker S...

Bio & Pharma Celltrion to break ground on CDMO plant in 2025: Chairman Seo

South Korea’s leading biosimilar developer Celltrion Inc. will break ground on its first contract development and manufacturing organization (...

Bio & Pharma Celltrion’s Remsima on course to become Korea’s 1st blockbuster drug

Celltrion Inc.'s Remsima, the world’s first biosimilar monoclonal antibody, is on track to exceed 1 trillion won ($713 million) in sales this ...

Bio & Pharma Samsung Bioepis gets EC's approval for Opuviz

South Korea's Samsung Bioepis Co., Samsung Biologics Co.'s fully owned biosimilar subsidiary, and the US-based Biogen said on Tuesday the European C...

Bio & Pharma Celltrion releases Steqeyma in Europe

South Korea's Celltrion Inc. said on Monday it released Steqeyma (ustekinumab) in Europe, the biosimilar of autoimmune disease treatment Stelara.T...

Mergers & Acquisitions SK Nexilis poised to sell thin film division to Affirma Capital

SK Nexilis Co., the world’s largest copper foil maker, is in the final stage of negotiations to sell its thin film manufacturing division to A...

Bio & Pharma Samsung Bioepis eyes record sales in 2024 after stellar Q3

Samsung Bioepis Co., Samsung Biologics Co.'s fully owned biosimilar subsidiary, is expected to post its best-ever annual revenue this year after sal...

Corporate strategy Apparel maker Hansae sets sights on auto parts business as growth driver

HO CHI MINH CITY – South Korean apparel maker Hansae Yes24 Group has set its sights on the auto parts business as a new growth driver to diver...

Mergers & Acquisitions Sono Hospitality to buy stake in Air Premia to bolster airline portfolio

Sono Hospitality Group, South Korea’s largest resort operator, will add low-cost carrier Air Premia Inc. to its bulging portfolio after agreei...

Batteries LG Energy aims to more than double sales to $50 billion by 2028

LG Energy Solution Ltd. has vowed to more than double its sales in five years to 67 trillion won ($50 billion) by diversifying its battery products ...

Bio & Pharma Celltrion earmarks billions of dollars to build CDMO plant: chairman

Celltrion Inc., South Korea’s largest biosimilar maker, will spend several billion dollars to build a factory to crack the contract developmen...